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Cytotoxic T lymphocytes (CTL) play an important role in the control
and elimination of infection by West Nile virus (WNV), yet the class
I human leukocyte antigen (HLA)-presented peptide epitopes that
enable CTL recognition of WNV-infected cells remain uncharacter-
ized. The goals of this work were first to discover the peptide
epitopes that distinguish the class I HLA of WNV-infected cells and
then to test the T cell reactivity of newly discovered WNV epitopes.
To discover WNV-immune epitopes, class I HLA was harvested from
WNV (NY99 strain)-infected and uninfected HeLa cells. Then pep-
tide epitopes were eluted from affinity-purified HLA, and peptide
epitopes from infected and uninfected cells were comparatively
mapped by mass spectroscopy. Six virus-derived peptides from five
different viral proteins (E, NS2b, NS3, NS4b, and NS5) were dis-
covered as unique to HLA-A*0201 of infected cells, demonstrating
that the peptides sampled by class I HLA are distributed widely
throughout the WNV proteome. When tested with CTL from
infected individuals, one dominant WNV target was apparent, two
epitopes were subdominant, and three demonstrated little CTL
reactivity. Finally, a sequence comparison of these epitopes with
the hundreds of viral isolates shows that HLA-A*0201 presents
epitopes derived from conserved regions of the virus. Detection
and recovery from WNV infection are therefore functions of the
ability of class I HLA molecules to reveal conserved WNV epitopes
to an intact cellular immune system that subsequently recognizes
infected cells.
epitope hierarchy  human leukocyte antigen  immunodominance 
major histocompatibility complex  mass spectrometry
West Nile virus (WNV) is a single-stranded positive senseRNA flavivirus that is related to other human pathogens
such as yellow fever virus and dengue fever virus. In nature, WNV
exists in an enzootic cycle between birds and mosquitoes, with other
species like horses and humans acting as incidental terminal hosts
(1, 2). In humans, WNV causes a nonspecific febrile illness with rare
cases of fatal encephalitis (3). Like other flaviviruses, WNV trans-
lates its genome into a polyprotein of 3,400 aa that is proteolyti-
cally cleaved into three structural proteins and seven nonstructural
proteins (4). In contrast to other RNA viruses, such as HIV and
influenza, WNV exhibits a high degree of sequence conservation in
its natural reservoir (5). Such sequence conservation makes WNV
a promising target with regard to targeting humoral and cellular
immune responses to conserved epitopes.
WNV elicits a strong immune response from innate and
adaptive branches of the immune system (6). With regard to
adaptive immunity, WNV infection results in the generation of
neutralizing antibodies that can protect mice from lethal infec-
tion when given passively (7–9), whereas mice deficient for
cytotoxic T lymphocytes (CTL) or class I major histocompati-
bility complex (MHC) exhibit increased viral burdens and in-
creased mortality (10–13). A key component of the cellular
antiviral immune response is the antigen-specific interaction of
T cell receptors and the class I MHC–peptide complex. Human
MHC class I, or the human leukocyte antigens (HLA), are a
complex consisting of a polymorphic  chain, 2-microglobulin,
and a peptide ligand of 8–13 residues. Class I HLA molecules
sample peptides that are representative of the intracellular
proteome and present their peptide cargo on the cell surface.
During viral infection, the proteome of the infected cell is altered
as are the peptides presented to CTL by class I HLA. Although
CTL recognize infected cells, the WNV epitopes presented by
class I HLA have not been reported. The goals of this work were
to identify peptide epitopes unique to infected cells and to assess
T cell recognition of these epitopes.
To discover WNV immune epitopes, class I HLA molecules were
gathered from infected and uninfected cells; then peptide epitopes
from infected and uninfected cells were comparatively mapped, and
peptides unique to infected cells were sequenced (14). Using this
direct epitope discovery approach, we identified viral-encoded
epitopes uniquely presented by HLA-A*0201 molecules of WNV-
infected cells. We found A*0201 to be extremely effective in its
interaction with WNV: highly conserved, high-affinity amino acid
sequences dispersed throughout the viral proteome were sampled
by class I HLA-A*0201. The discovered WNV epitopes were then
tested for cellular reactivity in an IFN- ELISPOT assay in WNV-
positive HLA-A*0201 patients. A hierarchy emerged whereby the
conserved high-affinity epitopes were dominant cellular immune
targets. These data represent a characterization of class I HLA-
presented WNV epitopes and indicate that cellular immune re-
sponses focus on a conserved subset of the available WNV epitopes.
Results
Production and Purification of HLA-A*0201-Specific Peptide Pools
from WNV-Infected Cells. The first objective of this work was to
understand the number and nature of class I HLA-presented
peptide epitopes unique to WNV-infected cells. Secreted class I
HLA proteins (sHLA) were used to produce a sufficient quantity
of peptides for comparative proteomics. To confirm that one set of
peptides in the comparative analysis were derived from infected
cells, we tested for viral RNA in the cells and in the sHLA-
containing culture supernatant. Florescence in situ hybridization
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(FISH) and real-time PCR (RT-PCR) confirmed the presence of
viral RNA in the cells and supernatant, respectively. Viral RNA was
detected 12 h after infection in the cells and in the supernatant (data
not shown). Optimally infected cell supernatant from days 0.5 to 5.5
after infection were pooled for affinity chromatography purifica-
tion. Infected and uninfected sHLA purified was 9.1 and 11 mg,
respectively, as determined by ELISA.
Comparative Ion Mapping Identifies Six WNV-Derived Peptides. Pools
of peptides eluted from class I HLA molecules contain thou-
sands of different peptides. To reduce the complexity of the
peptides before comparative analysis, peptides were separated
by reverse-phase HPLC (RP-HPLC) into fractions containing
200–250 peptides each (Fig. 1A). Similar HPLC elution pat-
terns for uninfected and infected peptide pools were obtained
(Fig. 1 A). MS ion maps were generated for corresponding
infected and uninfected HPLC fractions. These ion maps were
compared to identify ions unique to infected fractions. The vast
majority of ions were shared in the infected and uninfected MS
ion maps (Fig. 1B). Tandem mass spectrometry (MS/MS) se-
quence analysis of shared ions in the infected and uninfected ion
maps produced like sequences (data not shown), confirming the
alignment of HPLC fractions and overlap in the peptide prep-
arations. Fig. 1B shows an ion map generated from HPLC
fraction 63, where ion 524.8 was identified as unique to the
WNV-infected peptide pools. MS/MS fragmentation was per-
formed on ions unique to infected cells and individual peptide
sequences were determined (Fig. 1C). MS/MS fragmentation at
the same location in the corresponding uninfected fraction (and
neighboring uninfected fractions) confirmed the absence of this
peptide in uninfected cells. Fragmentation patterns between the
newly discovered WNV-derived peptides were compared with
synthetic peptide patterns to ensure sequence identity. Fig. 1C
shows the MS/MS fragmentation pattern of ion 524.8 (identified
as WNV-derived SLF9 peptide) overlaid with a synthetic peptide
demonstrating a correct sequence assignment. Finally, WNV-
derived peptides were assayed for their binding affinity to
HLA-A*0201. Fig. 1D demonstrates that SLF9 is a high-affinity
HLA-A*0201 ligand with an IC50 of 204 nM.
By using this direct comparative approach, six HLA-A*0201
WNV-derived peptides were identified from five different
viral proteins (E, NS2b, NS3, NS4b, and NS5) (Fig. 2 and Table
1). Five peptides were nonamers and one a decamer. Three of
the peptides (RLD10, SLF9, and SLT9) had a common A*0201
P2 leucine anchor residue, peptides YTM9 and ATW9 had a
threonine P2 anchor, and SVG9 had a valine at P2. At their C
terminus, A*0201 peptide ligands prefer a leucine or valine
anchor, and only SLT9 (C-terminal alanine) did not have a
common A*0201 C-terminal anchor. These putative WNV
epitopes fit the reported A*0201-binding motif. When tested
for binding to HLA-A*0201, these six WNV peptides were
found to be high-affinity binders with SLF9, SVG9, and YTM9
being the strongest binders, having an IC50 of 204, 247, and 291
nM, respectively (Table 1). The other peptides, SLT9, ATW9,
and RLD10, had comparatively lower affinities, with IC50
values of 503, 780, and 847 nM, respectively. The f luorescence
polarization assay used to assess A*0201 binding categorizes
peptides with IC50 values 5,000 nM as high affinity (15). In
Fig. 1. Direct epitope discovery of WNV epitope SLF9. (A) RP-HPLC profile of HLA-A*0201 peptides from uninfected (blue) and WNV-infected (red) cells. (B)
MS ion spectra of HPLC fraction 63 from uninfected (blue) and infected (red) cells. MS data were recorded for 300 scans. (C) Overlay of the MS/MS fragmentation
pattern of ion 528.4 in the infected HPLC fraction 63 (identified as the SLF9 peptide; red) with the MS/MS fragmentation pattern for the SLF9 synthetic peptide
(blue). (D) Florescence polarization competitive binding assay with the SLF9 synthetic peptide and HLA-A*0201.



















summary, we see that HLA-A*0201 presents six high-affinity
peptides derived from five different proteins throughout the
WNV proteome (Fig. 2).
CTL from Infected Individuals Recognize WNV Peptides. These WNV
peptide epitopes were tested for recognition by CTL from
HLA-A*0201 WNV-infected individuals. Peripheral blood
mononuclear cells (PBMCs) from WNV-infected patients were
tested in ELISPOT assays with the six identified WNV peptides.
To assess CTL responsiveness over time, we tested three sets of
CTL from HLA-A*0201 individuals: (i) the early set, PBMCs
isolated from individuals who had recently recovered from
infection (mean, 26.9 days after infection); (ii) the late set,
PBMCs isolated from individuals 1 year after infection; and
(iii) PBMCs from WNV-negative healthy controls. In both the
WNV early and late infection sets, PBMCs responded strongly
to SVG9 [mean  early, 125.3; late, 13.4 spot-forming units
(SFU) per 105 PBMCs] and SLF9 (mean  early, 48.0; late, 9.8
SFU per 105 PBMCs) with a moderate but significant response
in the early set to ATW9 (mean  13.6 SFU per 105 PBMCs)
compared with healthy controls. The WNV peptide epitopes
RLD10, YTM9, and SLT9, as a group, demonstrated no signif-
icant activity above the healthy controls in the both early and late
sets (Fig. 3). These data demonstrate an epitope hierarchy
whereby SVG9SLF9ATW9RLD10-SLT9-YTM9.
Although the early and late groups demonstrate a CTL response
to WNV epitopes, a significant decrease in the magnitude of the
CTL response is observed at the latter time point. For CTL that
respond to the SVG9 peptide, there is a 9.3-fold decrease in average
SFU from early to late, and for the SLF9 peptide there is a 4.9-fold
decrease, suggesting a reduction in the number of CTL available to
respond to specific WNV peptides over time (Fig. 3). The magni-
tude of CTL recall needed to confer immunity to subsequent
infection is unknown. These data demonstrate a hierarchical CTL
response to these newly discovered HLA-A*0201-restricted
epitopes in both early and late populations, with a reduction in
response at a later time after infection.
Heterogeneity Among Responses to HLA-A*0201-Restricted WNV
Epitopes. Having identified common trends in epitope hierarchy
and response strength (early and late; Fig. 3), we then analyzed
CTL response heterogeneity in three ways: (i) the magnitude of
each individual’s response to each epitope; (ii) each individual’s
epitope hierarchy; and (iii) the total number of epitopes recog-
nized by each individual’s CTL (Fig. 4). Responders were
categorized as high responders [100 SFU per 105 PBMCs (Fig.
4A)], medium responders [10–100 SFU per 105 PBMCs (Fig.
4B)], and low responders [10 SFU per 105 PBMCs (Fig. 4C)].
Eight individuals, six early and two late, were high responders
(Fig. 4A). Fifteen medium responders were identified, seven of
which followed the SVG9SLF9ATW9 hierarchy (Fig. 4B).
Twelve low responders were identified, and although a hierarchy
was not clear in many of these weak responders, responses to
SVG9 and SLF9 predominated (Fig. 4C). Five infected individ-
uals did not respond to WNV epitopes above background,
although two of these nonresponders did not recognize the
positive control peptides (data not shown); only 3 of 40 infected
A*0201 individuals with measurable CTL responses failed to
recognize the peptides discovered here.
Heterogeneity was observed in immune epitope hierarchies. (Fig.
4D Left). The largest grouping of donors (26 in total) responded to
SVG9 (red) as the dominant epitope. Of the 26 donors that
predominantly recognized SVG9, 19 recognized SLF9 (blue), and
5 recognized ATW9 (green) as a secondary epitope. Of the 19
donors that responded to SVG9 followed by SLF9, most (10 of 19)
responded to ATW9 as their third epitope. Five of the donors that
responded to SVG9SLF9ATW9 responded to RLD10 (yellow)
as their fourth. For 7 donors, the dominant epitope was SLF9 of
which 5 reacted to SVG9 as their second most dominant epitope.
Finally, donors were grouped by the number of epitopes to which
they responded (Fig. 4D Right). Few donors (2 of 40) responded to
only one epitope with four epitopes most commonly recognized (11
of 40 donors).
Fig. 2. Location of A*0201 WNV peptide epitopes on the WNV polyprotein. C, nucleocapsid; M, membrane; E, envelope glycoprotein; NS, nonstructural.
Table 1. Identified WNV-derived peptides
Peptide Sequence† Protein Location† IC50, nM
SVG9 SVGGVFTSV Env 430–438 247
RLD10 RLDDDGNFQL NS2b 78–87 847
YTM9 YTMDGEYRL NS3 518–526 291
SLF9 SLFGQRIEV NS4b 68–76 204
SLT9 SLTSINVQA NS4b 15–23 503
ATW9 ATWAENIQV NS5 862–870 780
†WNV NY99 polyprotein accession no. AAF20092.
Fig. 3. CTL reactivity of identified WNV epitopes. Shown are IFN- ELISPOT
assays with WNV peptides and PBMC isolated early (red) and late (blue) after
infection from WNV-positive individuals and healthy controls (green). *,
significant increase from healthy controls; †, significant increase from the late
set (blue). Significance was determined by Kruskal–Wallis one-way ANOVA
followed by Dunn’s method; P  0.05.



























Viral Sequence Homology of the Epitopes. We next examined se-
quence variability among reported WNV isolates to assess conser-
vation and divergence for these newly discovered A*0201 peptide
epitopes. Of the dominant epitopes, SVG9 was the most conserved,
with 97.2% (600 of 617 sequences) encoding the epitope sequence
we identified in the NY99 strain. Within SVG9, 1.6% (10 se-
quences) displayed a conservative valine to isoleucine substitution
at P2. The SLF9 and ATW9 epitopes demonstrated 86.1% (118 of
137) and 86.4% (171 of 198) homology among reported WNV
sequences. Variants of the SLF9 epitope altered 3 or 4 of the 9
residues in the epitope, whereas the most common variation of the
ATW9 epitope (11.1%) was a glutamate to histidine at P8. The
YTM9, SLT9, and RLD10 epitopes displayed 97.8% (134 of 137),
100% (137 of 137), and 97.1% (135 of 139) sequence homology with
reported WNV isolates, respectively. These data show that the
WNV peptide epitopes sampled by A*0201 are highly conserved
among hundreds of viral isolates.
Discussion
Several experimental observations can be gleaned from the endog-
enously processed WNV epitopes reported here. First is that the
WNV-encoded peptides clearly distinguish themselves by MS in-
tensity, as shown in Fig. 1B; the WNV peptides found here were
high-abundance peptides compared with numerous unchanged
host ligands. Another observation is that the six viral peptides were
derived from multiple proteins in the WNV proteome. We ob-
served that the class I molecule HLA-A*0201 was able to sample
epitopes from half of the viral proteins, both structural and non-
structural, during infection. These peptides were of high affinity for
A*0201 and were conserved among numerous WNV isolates.
An immune hierarchy emerged when these viral epitopes were
assayed by IFN- ELISPOT. As a group, three WNV epitopes were
recognized by CTL significantly above background:
SVG9SLF9ATW9 (Fig. 3A). Epitopes RLD10 and YTM9
displayed moderate reactivity, and SLT9 was the least immuno-
genic. Furthermore, there was a significant decrease in CTL
reactivity to WNV peptides in blood collected from infected
individuals at a later time point, indicating a loss of CTL specific for
WNV epitopes over time. Individual immune responses were
heterogeneous in their level of response, epitope hierarchy, and
number of total epitopes recognized. Moreover, there were no
statistically significant associations of age, gender, race, duration of
infection, and severity of disease with level of responses (data not
shown). Cumulatively, these data show that six WNV epitopes were
presented by A*0201, that most individuals recognized a dominant
target and an auxiliary epitope, and that a small group of patients
responded to five to six epitopes. Until now, this type of immune
response hierarchy has been impossible to envision because a
thorough survey of epitopes presented for recognition by the
cellular immune system had not been completed. Here, the direct
identification of WNV epitopes and subsequent immunogenicity
testing provides metrics for how HLA molecules reduce viral
proteins into a handful of optimal CTL targets.
The epitope hierarchy presented coincides with that seen in
mice. Two dominant epitopes have recently been identified in
mice during WNV infection. An E glycoprotein-derived
epitope is presented by the mouse class I MHC molecule
H-2Kb, and an NS4b epitope is restricted to H-2Db (16, 17). In
the Brien et al. work (16), the dominant H-2Db peptide epitope
accounted for 50–70% of the reactivity, and the remaining
Fig. 4. Heterogeneity among CTL responses. Patient-specific responses to WNV epitopes SVG9 (red), SLF9 (blue), ATW9 (green), RLD10 (yellow), YTM9 (purple),
and SLT9 (brown). (A) High responders, 100 SFU. (B) Moderate responders, 1–100 SFU. (C) Low responders, 10 SFU. Histograms represent the average number
of SFU per patient minus the healthy control (plus 2 SEM) and DMSO control. *, patient is from the early group. (D) (Right) Number of patients with a specific
epitope hierarchy. (Left) Number of epitopes to which each patient responded. Colored boxes, WNV epitopes as stated.



















CTL reactivity was dispersed among three other WNV peptide
epitopes. These murine data fit the observations presented
here in that we find a dominant SVG9 epitope along with
subdominant SLF9 and ATW9 epitopes presented by A*0201.
Moreover, these mouse studies reported a trend of dominant
epitopes having the highest binding affinities, of having mul-
tiple viral proteins sampled, and for having epitope sequences
conserved among numerous viral isolates (data not shown).
The discovery of conserved/dominant WNV epitopes pre-
sented by human MHC molecules in this work is therefore
consistent with observations in mice: dominant viral epitopes
are presented by MHC class I and efficiently targeted by CTL.
One would be hard pressed to arrive at a more eloquent
model of antigen presentation and cellular immune reactivity:
multiple epitopes in half of the viral proteins are sampled by
A*0201, a cellular immune response recognizes several of the
available viral epitopes, and conserved epitopes of high affin-
ity for A*0201 are preferentially targeted. These data are quite
powerful for two reasons. First, understanding how the im-
mune response successfully samples WNV epitopes provides a
comparative model as we try to elucidate host–pathogen points
of interaction with more elusive viruses such as HIV. Second,
we have confirmed that conserved WNV epitopes are endog-
enously loaded and presented to CTL by the class I of infected
cells. CTL-eliciting vaccines that use endogenous WNV
epitopes can be tested, and the presentation of confirmed
WNV epitopes by various HLA-A2 supertype members can be
ascertained. In summary, the direct discovery and subsequent
confirmation of viral CTL epitopes described here provide a
solid foundation for viral antigen presentation studies and
CTL vaccine design. These data provide an immune system
‘‘success story’’ whereby the nature of viral epitopes that are
endogenously sampled has been determined and the immune
response to these viral epitopes has been confirmed.
Materials and Methods
Virus and Cell Culture. WNV strain WNV NY99 was propagated on Vero E6
cell monolayers [American Type Culture Collection (ATCC) CRL-1586]. In-
fected cell supernatant was cleared of cell debris by centrifugation at
3,000  g for 15 min and stored at 80°C. HeLa (ATCC CCL-2) and Vero cells
were subcultured according to ATCC instructions in DMEM (Caisson Labo-
ratories, Inc.), 10% FBS (Serum Source International), and 1% penicillin/
streptomycin (Invitrogen).
sHLA-Secreting Transfectant Cell Line. HLA-A*0201 cDNA was amplified by
using a reverse oligonucleotide primer that truncated the 3 end of exon 4,
deleting the transmembrane and cytoplasmic domains. Furthermore, the 3
reverse oligonucleotide primer included a VLDLr purification epitope tag
(SVVSTDDDLA) that is recognized by the anti-VLDLr mAb (ATCC CRL-2197)
(18). The resulting PCR product was cloned into pcDNA 3.1 (Invitrogen) and
transfected by FuGENE 6 reagent (Roche) into HeLa cells. Quantification of
sHLA in supernatant was performed by using a sandwich ELISA, where an
antibody against the VLDLr epitope was the capture antibody, the primary
detector antibody was directed against 2-microglobulin (Dako Cytomation).
Viral Detection. WNV plaque assays were performed on both Vero and HeLa
monolayers as described in ref. 19. Rapid detection of WNV RNA in supernatant
was completed by using a TaqMan-based reverse-transcriptase RT- PCR. The
primers and probes used have been reported to detect the E region of WNV
genome (20). RT-PCR was performed by using the Applied Biosystems 7500
RT-PCR system under universal cycling conditions. Approximate plaque-forming
units (pfu) were determined from the Ct value using a standard curve [(y 
1.1145 Ln(x)  29.630); R2  0.9899, x range  1.2  101 to 1.2  106 pfu/ml].
Class I HLA from WNV-infected cells was required to detect epitopes unique
to infected cells. To confirm that HeLa cells were virus-infected, a FISH assay
and flow cytometry were performed (21). The probes used in this work were
18S rRNA (5-[Cy5]TCTAGCGGCGCAATACGAAT-3) as a positive control, 18S
rRNA reverse compliment (5-[Cy5]ATTCGTATTGCGCCGCTA-3) as a negative
control, and WNVE (5-[Cy5]GCCCGACCATGGGAGAAGCTC-3). Hybridized
cells were analyzed with a FACSCalibur flow cytometer (BD Biosciences).
Production and Isolation of HLA-A*0201 Peptides. sHLA-A*0201 peptide com-
plexes were produced in a bioreactor format as described in refs. 22–24. To
obtain sHLA from WNV-infected cells, bioreactors containing HeLa cells were
infected with 1.5  108 pfu (as determined by HeLa plaque assay) in a total
volume of 525 ml and recirculated in the bioreactor for 2 h before the harvest
of sHLA-containing supernatant was initiated. Supernatant from days 0.5 to
5.5 after infection were pooled for purification because we needed 12 h to
flush uninfected supernatant from the system. sHLA complexes were purified
by affinity chromatography with the anti-VLDLr epitope antibody. Acid-
eluted peptides were lyophilized and then fractionated by RP-HPLC with a
Jupiter Proteo 90 Å, 4 m, 150  2 column (Phenomenex) (14, 25).
MS Analysis and Peptide-Binding Assay. MS ion maps were generated for
HPLC fractions containing peptides. Fractions were ionized by using nano-
electrospray capillaries (Proxeon) into a QSTAR elite (Applied Biosystems)
electrospray quadrupole time-of-flight mass spectrometer. Peptide se-
quences were determined manually by using the MASCOT software pack-
age (Matrix Science). Peptide binding to HLA-A*0201 was determined by
using the florescence polarization method (Pure Protein L.L.C.) (16). WNV
peptide epitope sequence alignments were made by using CLC Free Work-
bench 3 (CLC Bio).
WNV Patient Samples. For the early sample group, peripheral blood was
collected from consenting donors (four men, four women) acutely infected
with WNV in heparinized tubes in accordance with a protocol approved by
Research Ethics Board at McMaster University. The median patient age was
62.5 years, with a range of 23– 81 years (mean  57.9 	 7.1 years). The
median time between onset of disease and the blood draw was 28.5 days,
with a range of 12– 46 days (mean  26.9 	 4.0 days). PBMCs were isolated
and cryopreserved in RPMI containing 12.5% human serum albumin
(Sigma) and 10% DMSO (Sigma) (26). HLA-A*02 expression was determined
by flow cytometry by using phycoerythrin-conjugated HLA-A*02 antibody
(clone BB7.2; Becton Dickinson).
For the late sample group, peripheral blood was collected from 32 WNV
antibody-positive subjects, recruited from high-incidence areas in the
central and southwest health districts of the State of Idaho. All persons had
been diagnosed with WNV in the summer of 2006, with confirmatory
testing conducted by the Idaho State Health Department. Subjects were
recruited between March and June 2007, and all gave informed consent
following approved Pittsburgh University IRB protocols. The median age of
the Idaho cohort was 50 years, and the range was 31– 88 years. After
collection, the PBMC fraction was isolated on Ficoll–Hypaque density
gradients and cryopreserved in 10% DMSO. Negative controls were anon-
ymous donors obtained from Pittsburgh Central Blood Bank. All subjects
were prescreened for HLA-A*02 by staining with antibody (clone BB7.2;
Becton Dickinson) and confirmed by HLA DNA-based typing.
IFN- ELISPOT. For the early sample group, ELISPOT assays were carried out
by using the human IFN- ELISPOT set (BD Biosciences) according to the
manufacturer’s instructions with 2 g/ml peptide. As a positive control,
PBMC samples were restimulated with peptide pools containing class I
restricted viral peptides specific for Epstein–Bar virus (EBV; 91 peptides),
cytomegalovirus CMV; 40 peptides), or influenza (47 peptides), respec-
tively. The flu peptides were selected from the Immune Epitope database
(27). The EBV and CMV peptides were described by Bihl et al. (28). For the
late sample group, human IFN- ELISPOT assays were carried out as de-
scribed in ref. 29. Briefly, PBMC were thawed, allowed to recover overnight
at 37°C, and then added to nitrocellulose-coated filter plates (Millipore) at
1  105 cells per well (triplicate wells per treatment). After -overnight
incubation with WNV peptides (10 g/ml) or control pool of 4 CMV, 15 EBV,
and 12 influenza virus (CEF) peptides (1 g/ml) representing a cross-section
of MHC class I dominant epitopes (30) or medium control, the plates were
developed, and spots were counted with an automated ELISPOT reader
(AID GmbH). All data are presented as SFUs per 105 PBMCs.
Statistical Analysis. For Fig. 3, significance was determined by Kruskal–Wallis
one-way ANOVA followed by Dunn’s method. A P value of 0.05 was con-
sidered significant. Statistical analysis was performed by using SigmaStat 3.0
software (SPSS, Inc.).
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